TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01145248

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double-balloon enteroscopy forceps biopsy
Description: An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: double-balloon enteroscopy forceps biopsy
Description: An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpapillary brush cytology
Description: An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transpapillary brush cytology
Description: An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
Study: NCT02674750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CUDC-907
Study: NCT00511160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Myocardial biopsies with TRU CUT 14 Gauge needle
Description: Myocardial needle biopsy and right atrial appendectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endomyocardial biopsies
Description: The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
Study: NCT05112198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of Noona web- based symptom tracking tool
Description: Noona patient reported outcome (PRO) platform tool that summarizes symptoms and distress
Study: NCT00991640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2-day preceptorship on obesity management
Study: NCT04682847

Intervention type: DRUG
Intervention: Ferumoxytol injection
Description: This is a prospective observation study of 1.5T MR-Linac-SPION imaging with Ferumoxytol for radiotherapy planning in patients with pre-existing liver condition in order to increase safety of liver SBRT with assessment of tumor and hepatic parenchyma response.
Study: NCT03955445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LNP023
Description: LNP023 capsules
Study: NCT01282840

Intervention type: DRUG
Group type: OTHER
Intervention: Tolterodine SR
Description: Tolterodine SR 4 mg qd
Study: NCT00174434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
Study: NCT01334372

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS
Description: First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
Study: NCT00913978

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: VitaHeat
Description: Patients will receive active warming via a heating mattress (VitaHEAT Medical) placed on the OR table with two thin sheets between the patient and the device; one covering the mattress and the other used as the draw sheet as usual practice. The device will be turned on 10 minutes prior to the patients' arrival to the operating room table. Patients' upper body will be covered with blankets. To increase skin surface contact with the mattress any blankets remaining under the patients' chest or head will be removed after intubation and replaced with a donut. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: Bair Hugger
Description: Patients will receive standard forced air warming applied to the upper body and turned on after the patient is prepped and draped. These warmers will be placed directly in contact with the skin without any intervening insulation. IV fluid warmer initiated on arrival to the operating room. The operating room temperatures will be adjusted to 21°C.
Study: NCT01977053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical and psychosocial phone calls
Description: The standard medical supervision is defined as follows:~* Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.~* Nominative notebook containing details of chemotherapy administered and medical contacts.~* Consultations with psycho-oncologist or psychiatrist (if necessary).~The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported.
Study: NCT00626236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: capsule taken three times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: capsule taken TID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: capsule taken TID
Study: NCT00042224

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy (ECT)
Description: ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: Patients with psychotic symptoms will receive clozapine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clozapine
Description: Patients with psychotic symptoms will receive clozapine
Study: NCT04316234

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive vape
Description: On days with passive vape, 2-3 vapers in an adjacent chamber were vaping by turn, and vape was passed on to the exposure chamber continuously .
Study: NCT01025999

Intervention type: OTHER
Intervention: No intervention
Study: NCT02060019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.
Study: NCT01156935

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laugh Yoga
Description: 1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
Study: NCT00563537

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 18F-X PET SCAN
Description: 18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
Study: NCT02101190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: Opicapone, OPC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: Opicapone, OPC
Study: NCT04670419

Intervention type: OTHER
Intervention: Viral clade
Description: Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection

Intervention type: OTHER
Intervention: Viral clade
Description: Disease outcomes are compared for patients infected with 2 different clades of a HEV gt 3 infection
Study: NCT00009646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indomethacin
Description: Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indomethacin
Description: 0.1 mg per kilogram of body weight

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.1 mg per kilogram of body weight
Study: NCT03963128

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplementation Vitamin D3
Description: Supplementation of vitamin D3 at a dose of 50.000 IU administered every two months (equivalent of 800 IU per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administred every two months
Study: NCT04514419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS627
Description: Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).
Study: NCT00626236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: capsule taken TID
Study: NCT00115349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deferoxamine
Description: Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferoxamine
Description: Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
Study: NCT02051595

Intervention type: OTHER
Group type: OTHER
Intervention: Vancomycin concentrations
Description: Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
Study: NCT04497272

Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 patients
Description: It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.
Study: NCT01838382

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: classic LMA insertion
Description: Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
Study: NCT01884402

Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Treatment as usual clinical practice

Intervention type: DRUG
Intervention: Ribavirin
Description: Treatment as usual clinical practice
Study: NCT00734942

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: support service
Description: * professional partners for communication~* befriending with other families concerned~* information and education (about illness, symptoms, first aid, caring)~* free-time activities and time out~* homework assistance~* administrative advise~* support for everyday life
Study: NCT02040311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 96 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate 192 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04344626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-operative brain tonometry
Description: Once the brain is exposed during surgery, a sterilized digital tonometer will be used to obtain brain tissue stiffness measurements at various locations of the cortex established based on results of pre-operative work-up. Precise stereotactic coordinates for each measurement will be recorded in a neuronavigation software to facilitate comparisons with results of other tests.
Study: NCT04532177

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: fractionated linear accelerator based SBRT to 40 Gy in 5 fractions
Study: NCT02580084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Intervention
Description: The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.~Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.~arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).~Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aorta femoral Bypass
Description: It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
Study: NCT04769752

Intervention type: OTHER
Intervention: collection of the allocated treatment
Description: collection of the allocated treatment

Intervention type: OTHER
Intervention: collection of the allocated treatment
Description: collection of the allocated treatment

Intervention type: OTHER
Intervention: collection of medical complications
Description: collection of medical complications

Intervention type: OTHER
Intervention: collection of medical complications
Description: collection of medical complications
Study: NCT01362426

Intervention type: DRUG
Intervention: paliperidone palmitate
Description: Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
Study: NCT02194023

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: PCB
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12%NF
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.03%NF
Description: Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PAT
Description: Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
Study: NCT03063424

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Eucapnic voluntary hyperventilation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Eucapnic voluntary hyperventilation

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Exercise challenge on a cycle ergometer

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Exercise challenge on a cycle ergometer
Study: NCT01884584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Description: Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
Study: NCT03663790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot Progression
Description: The intervention will be a gait retraining biofeedback focused on foot angle during gait trials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk Lean
Description: The intervention will be a gait retraining biofeedback focused on trunk lean angle during gait trials
Study: NCT00497250

Intervention type: DRUG
Group type: OTHER
Intervention: Gefitinib
Description: gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.

Intervention type: DEVICE
Group type: OTHER
Intervention: Radiation Therapy
Description: group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
Study: NCT04374799

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: two doses of heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: two doses of heparin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo
Study: NCT03498599

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Novelty facilitated extinction
Description: In the novelty-facilitated extinction design, the aversive outcome (i.e., mild unpleasant electrical pulse) is omitted and replaced by a low volume auditory tone.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Extinction
Description: During standard fear extinction the expected aversive outcome is omitted.
Study: NCT04047537

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Food Formulation 1
Description: WBF-0011

Intervention type: OTHER
Group type: OTHER
Intervention: Medical Food Formulation 2
Description: WBF-0011 (0.2X concentration)

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Placebo Capsules identical to those containing Formulation 1 and 2
Study: NCT01358149

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cocoa-based food
Description: single intake of cocoa-based food

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cocoa-based food
Description: Single intake of cocoa-based food
Study: NCT03442959

Intervention type: OTHER
Intervention: Data record
Description: characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)

Intervention type: OTHER
Intervention: Data record
Description: characteristics of patients, initial clinical presentation of TNE, management of TNE (primary tumor resection or conservative strategy), five years follow up (locoregional recurrence, complication due to the surgery, complications related to the conservative strategy, death)
Study: NCT04235972

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up consultation
Description: A follow-up consultation is organized which includes: A clinical examination with standard data collection as well as a face and profile radiograph of the operated wrist.
Study: NCT04452695

Intervention type: DEVICE
Intervention: Doctor Spot
Description: Robotic platform (Boston Dynamics) controlled by clinician with video interface to facilitate telemedicine triage
Study: NCT04514419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).
Study: NCT00411099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine
Study: NCT02722252

Intervention type: DEVICE
Intervention: Embryoscope

Intervention type: DEVICE
Intervention: Embryo culture system without incorporated camera
Study: NCT00759720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and glyburide
Description: TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-559 and glyburide
Description: TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glyburide
Description: TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
Study: NCT00411099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agomelatine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01526642

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non Invasive Ventilation
Description: NIV during night
Study: NCT01165658

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
Study: NCT01251354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495
Description: 1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops